MCID: MLG079
MIFTS: 42

Malignant Pleural Mesothelioma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 36 15 17 70
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 54

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
KEGG 36 H00015
MeSH 44 D000086002
NCIt 50 C7376
SNOMED-CT 67 254645002
ICD10 32 C45.0
UMLS 70 C0812413

Summaries for Malignant Pleural Mesothelioma

KEGG : 36 Malignant mesothelioma (MM) is a rare but very aggressive tumor that arises from mesothelial cells lining the pleural, peritoneal and pericardial cavities. Malignant pleural mesothelioma (MPM) is the most common type, accounting for about 70% of all MM cases. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The accumulation of numerous clonal chromosomal deletions in most MMs suggests a multistep process of tumorigenesis, characterized by the loss and/or inactivation of multiple tumor suppressor genes (TSGs). Cytogenetic and loss of heterozygosity (LOH) analyses of MMs have demonstrated frequent deletions of specific sites within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q, and 22q. Furthermore, TSGs within two of these regions, i.e., p16/CDKN2A-p14ARF at 9p21 and NF2 at 22q12, are frequently altered in MMs. Mutations of the p53 gene (TP53) are occasionally observed in MMs.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to benign mesothelioma and mesothelioma, malignant, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Malignant Pleural Mesothelioma is GAS5 (Growth Arrest Specific 5), and among its related pathways/superpathways is Adhesion. The drugs Vorinostat and Methylcobalamin have been mentioned in the context of this disorder. Affiliated tissues include t cells, lung and endothelial.

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 323)
# Related Disease Score Top Affiliating Genes
1 benign mesothelioma 32.6 WT1 THBD NKX2-1 MTAP MSLN CALB2
2 mesothelioma, malignant 32.1 WT1 THBD SPP1 NKX2-1 MUC1 MSLN
3 pneumothorax 31.5 NKX2-1 MUC1 CALB2
4 asbestosis 31.3 WT1 THBD MUC1 MSLN CALB2
5 sarcomatoid mesothelioma 31.1 WT1 THBD NKX2-1 MUC1 MSLN CALB2
6 malignant peritoneal mesothelioma 31.0 MUC1 BIRC5
7 lung cancer susceptibility 3 31.0 NKX2-1 MUC1 MSLN GAS5 CDH2 CALB2
8 peritoneal mesothelioma 30.9 WT1 THBD MUC1 CALB2
9 pleural cancer 30.8 WT1 TYMS SPP1 MTAP MSLN CALB2
10 thyroid carcinoma 30.7 PVT1 NKX2-1 GAS5
11 sarcoma, synovial 30.7 WT1 MUC1 CALB2
12 pericardial mesothelioma 30.6 MUC1 CALB2
13 osteogenic sarcoma 30.6 WT1 SPP1 PVT1 GAS5
14 thymic carcinoma 30.6 NKX2-1 MUC1 CALB2
15 wilms tumor 1 30.5 WT1 NKX2-1 MUC1 CDH2 CALB2 BIRC5
16 colorectal adenocarcinoma 30.5 TYMS NKX2-1 MUC1
17 lung sarcomatoid carcinoma 30.4 THBD NKX2-1 MUC1 CALB2
18 clear cell renal cell carcinoma 30.3 PVT1 MUC1 CALB2 BIRC5
19 pancreatic cancer 29.9 TYMS PVT1 MUC1 MSLN GAS5 ENSG00000261211
20 renal cell carcinoma, nonpapillary 29.9 WT1 SPP1 PVT1 NKX2-1 MUC1 MSLN
21 pleural disease 10.8
22 rare tumor 10.8
23 neutropenia 10.8
24 adenocarcinoma 10.7
25 asbestos intoxication 10.7
26 lung cancer 10.6
27 virus-associated trichodysplasia spinulosa 10.6
28 severe combined immunodeficiency 10.6
29 pleurisy 10.6
30 pleural empyema 10.5
31 thrombocytopenia 10.5
32 benign pleural mesothelioma 10.5
33 lung sarcoma 10.5 NKX2-1 CALB2
34 thrombocytosis 10.5
35 cervical carcinosarcoma 10.5 CALB2 BIRC5
36 adenofibroma 10.5 MUC1 CALB2
37 adult malignant schwannoma 10.5 SPP1 BIRC5
38 respiratory failure 10.5
39 pulmonary embolism 10.5
40 fallopian tube carcinosarcoma 10.5 WT1 CALB2
41 epididymal neoplasm 10.5 WT1 CALB2
42 spindle cell thymoma 10.5 MUC1 CALB2
43 testicular fibroma 10.5 WT1 CALB2
44 wolffian duct adenocarcinoma 10.5 WT1 CALB2
45 ovarian germ cell teratoma 10.5 NKX2-1 CALB2
46 mucinous stomach adenocarcinoma 10.5 NKX2-1 CALB2
47 pancreatic mucinous cystadenoma 10.4 MUC1 CALB2
48 ovarian endometrioid stromal sarcoma 10.4 WT1 CALB2
49 esophagitis 10.4
50 juvenile type testicular granulosa cell tumor 10.4 WT1 CALB2

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


fatigue; dyspnea; chest pain; chills; malaise

Drugs & Therapeutics for Malignant Pleural Mesothelioma

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vorinostat Approved, Investigational Phase 3 149647-78-9 5311
2
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
3
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
4
Raltitrexed Approved, Investigational Phase 3 112887-68-0 104758
5
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
6
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
7
Gemcitabine Approved Phase 3 95058-81-4 60750
8
Pembrolizumab Approved Phase 2, Phase 3 1374853-91-4
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
10
Nintedanib Approved Phase 2, Phase 3 656247-17-5 56843413
11
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
12
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
13
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
14 Antiemetics Phase 3
15 Histone Deacetylase Inhibitors Phase 3
16 Vitamins Phase 2, Phase 3
17 Vitamin B12 Phase 2, Phase 3
18 Vitamin B 12 Phase 2, Phase 3
19 Angiogenesis Inhibitors Phase 2, Phase 3
20 Mitomycins Phase 3
21 Mitogens Phase 3
22 Endothelial Growth Factors Phase 3
23 interferons Phase 3
24 Interferon-alpha Phase 3
25 Interferon alpha-2 Phase 3
26 Tin Fluorides Phase 3
27 Anti-Infective Agents Phase 3
28 Antiviral Agents Phase 3
29 Antimetabolites Phase 3
30 Tubulin Modulators Phase 3
31 Antimitotic Agents Phase 3
32 Antibodies Phase 3
33 Immunoglobulins Phase 3
34 Antibodies, Monoclonal Phase 3
35 Vinca Alkaloids Phase 3
36
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
37
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
38
Axitinib Approved, Investigational Phase 1, Phase 2 319460-85-0 6450551
39
tannic acid Approved Phase 2 1401-55-4
40
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
41
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
42
Belinostat Approved, Investigational Phase 2 866323-14-0
43
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
44
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
45
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 93860 387447
47
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
48
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
49
Lenvatinib Approved, Investigational Phase 2 417716-92-8
50
Fludarabine Approved Phase 1, Phase 2 21679-14-1, 75607-67-9 30751

Interventional clinical trials:

(show top 50) (show all 158)
# Name Status NCT ID Phase Drugs
1 NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2 A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy Completed NCT00128102 Phase 3 Vorinostat;Placebo
3 A Randomized Controlled Trial of Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4 A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
5 A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
6 Phase III Study of Tomudex and Cisplatin Versus Cisplatin in Malignant Pleural Mesothelioma Completed NCT00004920 Phase 3 cisplatin;raltitrexed
7 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
8 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Recruiting NCT03710876 Phase 3 Celecoxib Oral Product;Gemcitabine
9 A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma Recruiting NCT03762018 Phase 3 Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
10 Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) Recruiting NCT04158141 Phase 3 Carboplatin;Cisplatin;Pemetrexed;Pemetrexed Disodium
11 A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma Active, not recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
12 A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Active, not recruiting NCT02784171 Phase 2, Phase 3 Cisplatin;Pemetrexed;Pembrolizumab
13 LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma Terminated NCT01907100 Phase 2, Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
14 PIT: A Phase III Randomised Trial of Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Following Invasive Chest Wall Intervention Terminated NCT01604005 Phase 3
15 A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma Unknown status NCT02568449 Phase 2 Nintedanib
16 Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
17 Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma. Unknown status NCT01869023 Phase 2 Gemcitabine;Cisplatin
18 "Phase II Study: Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma " Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
19 A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
20 Aggressive Multi-Modality Management of Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
21 A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma Unknown status NCT02139904 Phase 2 Vinorelbine
22 A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
23 A Phase II Trial of Low-dose Gemcitabine in Prolonged Infusion and Cisplatin in Treatment of Malignant Pleural Mesothelioma Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
24 NGR010: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Previously Treated With no More Than One Systemic Therapeutic Regimen Completed NCT00484276 Phase 2 NGR-hTNF
25 Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
26 A Phase II Study to Investigate the Activity and Safety of Anti-PD-L1 Antibody (Durvalumab) In ADvancEd Pretreated Malignant Pleural Mesothelioma - DIADEM Study Completed NCT04115111 Phase 2 Durvalumab
27 A Phase II Trial of Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma (MPM)) Completed NCT01112293 Phase 2 GC1008
28 A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study Completed NCT02497508 Phase 2 nivolumab
29 Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
30 Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
31 A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy Completed NCT01211275 Phase 1, Phase 2 chemotherapy
32 A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma Completed NCT02347917 Phase 1, Phase 2 BBI608;Pemetrexed;Cisplatin
33 Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma Completed NCT03177668 Phase 1, Phase 2 YS110
34 Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma: a Phase II Study. Acronym: INITIATE Completed NCT03048474 Phase 2 nivolumab and ipilimumab
35 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
36 Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
37 A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma Completed NCT01590160 Phase 1, Phase 2 Ganetespib
38 A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma Completed NCT02397928 Phase 2 Pemetrexed;Cisplatin or Carboplatin
39 Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma Completed NCT02662504 Phase 2 Adjuvant chemotherapy
40 Phase II Study of Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
41 A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
42 ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM) Completed NCT02194231 Phase 2 Trabectedin
43 An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
44 Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy Completed NCT02049060 Phase 1, Phase 2 Tivantinib
45 NGR019: Randomized Double-blind Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma (MPM) Completed NCT01358084 Phase 2 NGR-hTNF;Placebo
46 Phase II Study of PXD101 (NSC 726630) as Second-Line Therapy for Treatment of Patients With Malignant Pleural Mesothelioma Completed NCT00365053 Phase 2 belinostat
47 A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma Completed NCT00243074 Phase 2 cediranib maleate
48 Surgery and Intracavitary Photodynamic Therapy (PDT) for the Treatment of Malignant Pleural Mesothelioma; The Use of Light Delivery Fibers With Large Diffusers Completed NCT00054002 Phase 2 porfimer sodium
49 A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
50 A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients Completed NCT02716272 Phase 2 Nivolumab;Nivolumab + Ipilimumab

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

40
T Cells, Lung, Endothelial, Lymph Node, Thyroid, Spinal Cord, Breast

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 4087)
# Title Authors PMID Year
1
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. 54 61
20177021 2010
2
Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. 61 54
20075387 2010
3
Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. 61 54
19302997 2009
4
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro. 61 54
19528482 2009
5
Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. 54 61
19201924 2009
6
Osteopontin is not a specific marker in malignant pleural mesothelioma. 61 54
19634115 2009
7
Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. 54 61
19516197 2009
8
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. 61 54
18827603 2008
9
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. 61 54
18394747 2008
10
Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. 61 54
18670302 2008
11
Prognostic role of osteopontin expression in malignant pleural mesothelioma. 61 54
18550471 2008
12
Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. 54 61
18422869 2008
13
[Renal cell carcinoma with malignant pleural mesothelioma after asbestos exposure: a case report]. 54 61
18051806 2007
14
Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. 54 61
17646232 2007
15
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. 54 61
17671130 2007
16
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma. 54 61
17290392 2007
17
Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma. 54 61
17493236 2007
18
Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. 54 61
17504993 2007
19
Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. 54 61
17279584 2007
20
Molecular basis of antifolate resistance. 61 54
17333344 2007
21
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. 54 61
16294031 2006
22
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. 61 54
15447976 2005
23
The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2. 54 61
12940775 2003
24
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment. 54 61
12800189 2003
25
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. 61 54
12479365 2002
26
Detection and quantification of SV40 large T-antigen DNA in mesothelioma tissues and cell lines. 54 61
11956641 2002
27
Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. 54 61
11307155 2001
28
Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma. 61 54
10737384 2000
29
A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours. 61 54
9639123 1998
30
Manganese superoxide dismutase in healthy human pleural mesothelium and in malignant pleural mesothelioma. 61 54
9533946 1998
31
Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. 61 54
9692834 1998
32
Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. 54 61
1357974 1992
33
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression. 61
33795785 2021
34
Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. 61
33259933 2021
35
Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro. 61
33336399 2021
36
Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study. 61
32791881 2021
37
Commentary: Winning the battle for local control without losing war for survival against malignant pleural mesothelioma. 61
32741628 2021
38
Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma. 61
32631662 2021
39
Prognostic factors for progression-free and overall survival in malignant pleural mesothelioma. 61
33660947 2021
40
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma. 61
33238762 2021
41
Commentary: Cisplatin-induced nephrotoxicity following cytoreductive surgery and heated intraoperative chemotherapy for malignant pleural mesothelioma. 61
32771233 2021
42
Clinical prognostic factors in pleural mesothelioma: best supportive care and anti-tumor treatments in a real-life setting. 61
33502280 2021
43
Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: An autopsy case report. 61
33605078 2021
44
Impact of CT convolution kernel on robustness of radiomic features for different lung diseases and tissue types. 61
33544646 2021
45
Diaphragm reconstruction by GORE DUALMESH in patients undergoing resection for thoracic malignancies. 61
33789706 2021
46
The Association between Malignant Pleural Mesothelioma and Thoracic Radiation Therapy for Hodgkin's Lymphoma: The First Case Report in Japan. 61
33055477 2021
47
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. 61
33743636 2021
48
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. 61
33685408 2021
49
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival. 61
32842027 2021
50
RapidPlan for Knowledge-Based Planning of Malignant Pleural Mesothelioma. 61
32562788 2021

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3P Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss LINC00032 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 MUC1 MSLN CDH2

GO Terms for Malignant Pleural Mesothelioma

Cellular components related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apicolateral plasma membrane GO:0016327 8.62 THBD CDH2

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....